Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Disorders01:29

Bone Disorders

3.9K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
3.9K
Bone Remodeling01:40

Bone Remodeling

38.5K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
38.5K
What is the Skeletal System?01:02

What is the Skeletal System?

53.6K
Overview
53.6K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

3.2K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.2K
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

2.9K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
2.9K
The Functions of the Skeletal System01:22

The Functions of the Skeletal System

4.3K
The most apparent functions of the skeletal system are support, protection, and movement. However, bone tissue also performs several other critical metabolic functions. For one, the bone matrix acts as a reservoir for a number of minerals important to the functioning of the body, especially calcium and phosphorus. These minerals, present in the bone tissue, can be released back into the bloodstream when required. Calcium ions, for example, are essential for muscle contractions and controlling...
4.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Technology in Diabetes: A Year in Review.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2026
Same author

Thyroid Storm With Multiorgan Dysfunction Mimicking Sepsis: Thionamide-Sparing Bridge to Delayed Carbimazole.

Cureus·2026
Same author

Managing diabetic ketoacidosis in special conditions: Difficulties and dilemmas.

World journal of diabetes·2025
Same author

Role of Anabolic Anti-Osteoporosis Therapy in Diabetes Subjects.

Indian journal of endocrinology and metabolism·2025
Same author

Diagnostic approach to rickets: an Endocrine Society of Bengal (ESB) consensus statement.

Annals of pediatric endocrinology & metabolism·2024
Same author

Immunotherapy in type 1 diabetes: Novel pathway to the future ahead.

World journal of diabetes·2024

Related Experiment Video

Updated: Sep 9, 2025

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation
07:17

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation

Published on: April 14, 2016

84.7K

Hepatic osteodystrophy: An underrecognized metabolic bone disease.

Subhodip Pramanik1, Rajan Palui2, Sayantan Ray3

  • 1Department of Endocrinology, Neotia Getwel Healthcare Centre, Siliguri 734010, West Bengal, India.

World Journal of Hepatology
|September 3, 2025
PubMed
Summary

Hepatic osteodystrophy (HO) is a common bone complication in chronic liver diseases (CLD), often leading to osteoporosis. Management requires individualized assessment and risk factor mitigation, though effective treatments are still under investigation.

Keywords:
BisphosphonatesChronic liver diseaseHepatic osteodystrophyManagementPathogenesisVitamin D

More Related Videos

Using Real-Time Cell Metabolic Flux Analyzer to Monitor Osteoblast Bioenergetics
09:43

Using Real-Time Cell Metabolic Flux Analyzer to Monitor Osteoblast Bioenergetics

Published on: March 1, 2022

3.3K
The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
03:52

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy

Published on: February 21, 2025

498

Related Experiment Videos

Last Updated: Sep 9, 2025

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation
07:17

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation

Published on: April 14, 2016

84.7K
Using Real-Time Cell Metabolic Flux Analyzer to Monitor Osteoblast Bioenergetics
09:43

Using Real-Time Cell Metabolic Flux Analyzer to Monitor Osteoblast Bioenergetics

Published on: March 1, 2022

3.3K
The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
03:52

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy

Published on: February 21, 2025

498

Area of Science:

  • Hepatology
  • Endocrinology
  • Bone Metabolism

Background:

  • Hepatic osteodystrophy (HO) is a frequent complication of chronic liver diseases (CLD), presenting as osteoporosis or osteopenia.
  • It affects patients with various CLD etiologies, including chronic cholestasis and cirrhosis.
  • The prevalence of bone density loss is notably increased in CLD patients.

Purpose of the Study:

  • To provide an updated review of hepatic osteodystrophy (HO) in chronic liver diseases (CLD).
  • To cover the pathogenesis, management strategies, and current treatment interventions for HO.
  • To highlight the need for further research in defining optimal management and treatments for HO.

Main Methods:

  • Review of existing literature on hepatic osteodystrophy (HO) and chronic liver diseases (CLD).
  • Analysis of multifactorial pathogenetic mechanisms, including genetic, nutritional, hormonal, and lifestyle factors.
  • Evaluation of current diagnostic approaches focusing on fracture risk and bone mineral density.

Main Results:

  • HO pathogenesis is multifactorial, involving genetic factors, vitamin deficiencies, inflammation, hypogonadism, hyperbilirubinemia, and therapies.
  • Management necessitates individualized assessment of fracture risk and bone mineral density.
  • Prevention strategies include risk factor mitigation, treating hypogonadism, and promoting healthy lifestyle choices.

Conclusions:

  • Current treatment for HO primarily involves bisphosphonates, but their efficacy in fracture reduction is inconsistent.
  • Further research is essential to establish definitive management protocols and specific treatments for HO.
  • Improved understanding and treatment of HO are crucial for preventing fragility fractures and enhancing the quality of life for CLD patients.